2 results
Approved WMOCompleted
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI207127 in combination with 120 mg QD Faldaprevir and RBV for 16 and 24 weeks in target chronically infected HCV GT1b treatment naïve patients, including a…
Approved WMORecruiting
The main objective of this study is to investigate whether rTMS treatment will improve clinical outcomes in body dysmorphic disorder, by reducing BDD YBOCS outcomes. Furthermore to improve localization and rTMS treatment in the dorsolateral…